GlaxoSmithKline shares were at a peak of 1,846p just before the pandemic began in January 2020, since then GSK had followed a downtrend up until March 2021. Economies around the world faced a slowdown in March 2021, which would explain the drop in GlaxoSmithKline shares as well. However, since then the GSK share price has […]

The post GlaxoSmithKline shares: the best FTSE 100 Pharma buy? appeared first on UK Investor Magazine.

The COVAX Facility is led by the Gavi vaccine alliance group, and has the goal of allowing companies and researchers to collaborate, and develop, produce and provide equitable access to COVID tests, treatments and vaccines. In service of this alliance, UK health giant GSK (LON:GSK) and French pharma blue chip Sanofi (EPA:SAN) have signed a […]

The post GSK and Sanofi sign Statement of Intent to provide 200m COVID vaccines appeared first on UK Investor Magazine.

Around the world, pharmaceutical companies and governments are working at record speed to develop a vaccine for the novel coronavirus. There are currently more than 150 potential vaccines in development, with high hopes that an effective product can be introduced to the market within the next year. The demand for a vaccine has increased since […]

The post AstraZeneca and GlaxoSmithKline – the Covid-19 vaccine frontrunners to watch appeared first on UK Investor Magazine.

GlaxoSmithKline (LON:GSK) have seen their profits rise across 2019 as the pharmaceutical titan updated the market on its 2019 and fourth quarter operations. Glaxo alluded to the improvements particularly in its vaccines and consumer health segments, and also the benefits exploited from its mutual venture with Pfizer (NYSE:PFE). The pharmaceutical giant said that it had […]

The post GlaxoSmithKline round off excellent 2019 with bullish fourth quarter update appeared first on UK Investor Magazine.

FTSE 250 specialist pharmaceutical company Indivior Plc (LON:INDV) announced on Wednesday that it has released an authorised generic version of its treatment to combat opioid addiction. The treatment has been released in the US market in an attempt to combat the anticipated impact of rival companies launching ‘copycat’ products. The decision to launch the treatment […]

The post Indivior releases new treatment, shares dip with copycat fears appeared first on UK Investor Magazine.

British pharmaceutical firm GlaxoSmithKline (LON:GSK) have posted a 36% on-year hike in full-year profits, though the company have warned investors of the potential for turbulent conditions later in 2019. The news follows today’s announcement of a new rare disease treatment by the company’s counterpart AstraZeneca (LON:AZN), strong trade amid the FTSE slump mid-2018 and a […]

The post GlaxoSmithKline profits up 36% – warnings for 2019 appeared first on UK Investor Magazine.

GlaxoSmithKline Plc (LON:GSK) have secured approval for a licence extension of their Nucala treatment for children with severe asthma. The treatment was first received patent and distribution approval in 2015 and is the first method of pediatric care that directly combats the effects of interleukin-5 (IL-5), which regulates the function of eosinophils. In preliminary trials, […]

The post GSK secure approval for Nucala asthma treatment appeared first on UK Investor Magazine.

GlaxoSmithKline (LON:GSK) continues to rally and avoid the more bleak fate being faced by some of its FTSE 100 counterparts. GSK’s share price has progressed in its usual manner, with an incremental rise of 0.16 percent since trading opened this morning; the price going from 1505.2-1513.6 GBX in the first five minutes of trading. This […]

The post GlaxoSmithKline shares rally and buck the FTSE trend appeared first on UK Investor Magazine.